Status:
TERMINATED
Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia
Lead Sponsor:
Pfizer
Conditions:
Fibromyalgia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate the lon-term safety and tolerability of \[S,S\]-reboxetine in patients with fibromyalgia
Eligibility Criteria
Inclusion
- Diagnosis of patients meeting the ACR criteria for fibromyalgia (i.e. widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites)
Exclusion
- Patients with other severe pain (e.g. DPN and PHN) that may confound assessment or self-evaluation of the pain associated with fibromyalgia
Key Trial Info
Start Date :
October 20 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 18 2009
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00607256
Start Date
October 20 2007
End Date
May 18 2009
Last Update
December 13 2019
Active Locations (79)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Orangevale, California, United States, 95662
2
Pfizer Investigational Site
Santa Ana, California, United States, 92705
3
Pfizer Investigational Site
Denver, Colorado, United States, 80239
4
Pfizer Investigational Site
Jacksonville, Florida, United States, 32216